-=MacroGenics (MGNX) reported earnings on Tue 5 May 20 (a/h)

MacroGenics (MGNX) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $0.99 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 9.90%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.71 per share when it actually produced a loss of $0.62, delivering a surprise of 12.68%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

MacroGenics, which belongs to the Zacks Medical - Products industry, posted revenues of $13.68 million for the quarter ended March 2020, surpassing the Zacks Consensus Estimate by 84.12%. This compares to year-ago revenues of $9.66 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

MacroGenics shares have lost about 34.3% since the beginning of the year versus the S&P 500's decline of -12%.

Earnings this week : May 4 - 8, 20 (wk 19)

Monday (May 4)

• Morning: PETS GATX KELYA PFGC NNN PETS PBI TSN WAB WEC WLK 
• Afternoon:  ACHC ALSN AIG AWR CAR CHGG DLB FN FIVN FRPT ITRI JKHY KMT KN LEG LMNX MHK MOS RMBS O RBC REXR SHAK SWKS SYKE THC TXRH TREX VNOM VNO WWD XPO

Tuesday (May 5)

• Morning: ACM AER AMCX APTV ARMK ARCC DBD D DD DEA FCAU GPI HSIC ITW INCY INGR IPGP JELD JLL TREE LGIH LPX LITE MNK MPC SBSI SYY TRI BLD TDG USCR USFD W WBT WRK
• Afternoon: ATVI ANET BYND BLKB CAMP CAKE COHU CMP DVA DK DVN EA ICFI IOSP INGN INSP NVTA JAZZ KGC KLAC LC LPSN DOOR MTCH MATX MAT MELI MEOH MGNX MODN MYGN NVRO ONTO PINS PAA PLNT PRO PRU SFM STOR VRSK VOYA DIS WU

Wednesday (May 6)

• Morning: AEIS ALXN ARES ASTE BWA BG CARS CBZ CDW FUN IMOS CNHI CGEN CVS DISCA GCP GM GEL GPC ROCK GPN KL KKR MYE NYT DNOW NS ODP OMI PZZA PSN PAG SBH STNG SMG SHOP TMHC TNC MEET VMC WD WM WEN WING WYND ZTS
• Afternoon: DDD ADTN ALB AYX AMED AEL AWK AMP ANGI ANSS APA AZPN ATO AVB BNFT BIO BEAT EPAY BFAM BRKR CCMP CVNA CTL CDAY CF CHEF XEC CPA CXW CSGS CUB CW DAR DCP DRQ ENTA EPR EQIX ESE ESPR WTRG ESS ETSY RE EVRG ES EXAS STAY EXR FSLY FRT FG FORM FTNT FCPT FOXA FOXF FNV GBT GDDY GRUB HR HI HUBS H IMMU INSG IAC INVH IRWD KRO LCI LGND LNC LVGO LYFT CLI MX MFC MRO MET MAA NTRA NBIX LASR NMIH NDLS NUS NTR NUVA OSUR PAAS PYPL PTON PING PXD PPD QTWO QGEN QDEL RDN RMAX RP RNR RCII REZI RNG RGLD SRPT SEDG SONO SJI SAVE SQ STAA SRI RUN TMUS TLND TTGT REAL TIVO TRMB TSE TROX TWLO TWO UDR UGI RARE UPWK VVV VIAV WCN WTS WELL WPM WPX WYNN ZIXI ZNGA 

Thursday (May 7)

• Morning: AAON AAN ACIW GOLF AES ABC BUD MT AAWW BLL BHC BCE BDX BV BMY CNQ CNNE CBRE CNP ECOM CRL CWEN CCOI CFX COMM CTB CORE CTVA DHR DISH SATS EPC EDIT ELAN ENB ENDP ENR EPAM EQT EXLS FIS FVRR FOCS IT THRM GTN HAIN HL HES HLT HIMX HFC HII NSIT IART NTLA IDCC IRM JBLU KAR KTB LAMR LAUR LXP MGA MBUU MMS MD MIDD MRNA MUR EYE NTCT NOMD OGE PCRX PEGI PENN PRFT DOC PBH PWR RTX RHP SERV SHLX SPAR SRCL TGNA TU TEVA TW THS VIAC VIRT VSTO VG WEX XEL YETI 
• Afternoon: ADT AL ALRM APPN AAXN BECN BILL BJRI BKNG CTSH SCOR ED CCRN DBX ENV EOG FSLR FISV GLUU GPRO LOPE GH HLF ICUI IPHI PODD ITGR LHCG LSI LYV MTW VAC MCHP MNST NWSA NUAN OMCL PDCE PEB PBA PRAA PFPT PBYI QRVO QLYS RPD RDFN RBA ROKU SKYW STMP SPWR SVMK SYNA TDC TTD TRUE TCX UBER OLED UPLD ECOL YELP ZG 

Friday (May 8) 

• Morning: AXL ATH AVA BLMN BPMP BR BIP CATM REOAD CRON UFS ESNT EVTC EVOP EXC GTT HEES HSC HMSY TWNK TILE KIM LEA NJR NBL OUT PBF PNW PPL SABR SSP SEAS SR SHO SWCH TEN VTR

*******

Earnings spotlight: Tyson Foods (NYSE:TSN), Shake Shack (NYSE:SHAK), Skyworks Solutions (NASDAQ:SWKS), Freshpet (NASDAQ:FRPT) and Chegg (NYSE:CHGG) on May 4; Marathon Petroleum (NYSE:MPC), Fiat Chrysler Automobiles (NYSE:FCAU), Sysco (NYSE:SYY), Beyond Meat (NASDAQ:BYND), US Foods (NYSE:USFD), DuPont (NYSE:DD), Activision Blizzard (NASDAQ:ATVI), Disney (NYSE:DIS), Prudential (NYSE:PRU), Allstate (NYSE:ALL) and Dominion Energy (NYSE:D) on May 5; CVS Health (NYSE:CVS), General Motors (NYSE:GM), Bunge (NYSE:BG), Barrick (NYSE:GOLD), MetLife (NYSE:MET), T-Mobile US (NASDAQ:TMUS), Etsy (NASDAQ:ETSY), Shopify (NYSE:SHOP), Peloton Interactive (NASDAQ:PTON) and PayPal (NASDAQ:PYPL) on May 6; AmerisourceBergen (NYSE:ABC), JetBlue (NASDAQ:JBLU), Booking Holdings (NASDAQ:BKNG), Raytheon Technologies (NYSE:RTX), Anheuser-Busch InBev (NYSE:BUD), Bristol-Myers Squibb (NYSE:BMY), ViacomCBS (NASDAQ:VIAC), Baidu (NASDAQ:BIDU), Uber (NYSE:UBER), News Corp (NASDAQ:NWSA) and Post Holdings (NYSE:POST) on May 7; and SeaWorld Entertainment (NYSE:SEAS), Cronos (NASDAQ:CRON) and PBF Energy (NYSE:PBF) on May 8.

This week's biggest % winners & losers : Feb. 4 - 8, 19 (wk 6)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: MGNX (22.44 +96.33%), EOLS (26.71 +45.72%), OMCL (76.8 +19.18%)
• Materials: SBGL (4.3 +16.85%)
• Industrials: TGI (21.68 +20.38%), MLI (31.52 +18.23%)
• Consumer Discretionary: MAT (15.23 +24.63%), COLM (106.86 +18.97%), SKX (31.91 +18.67%), HBI (17.84 +17.45%), IRBT (104.17 +17.03%), OSTK (20.36 +16.01%)
• Information Technology: ULTI (332.41 +19.65%), FSCT (36.44 +18.08%), PAYC (175.96 +16.65%), MODN (16.78 +16.45%), APPN (36.78 +16.06%)
• Consumer Staples: COTY (9.33 +23.74%)

This week's top 20 % losers

• Healthcare: SLDB (7.42 -69.36%), SGMO (7.72 -38.14%), OPK (2.69 -25.07%), VCRA (32.33 -21.36%), OSUR (10.85 -17.11%)
• Industrials: PRLB (103.49 -16.87%)
• Consumer Discretionary: TTM (10.51 -18.53%)
• Information Technology: ARLO (3.66 -50.74%), CALX (7.4 -33.03%), CARB (23.85 -16.72%)
• Energy: SRCI (4.15 -17.82%), DNR (1.71 -17.39%), BTU (29.73 -16.89%), ECR (0.96 -15.94%), CHK (2.39 -15.85%), STNG (15.59 -15.64%)
• Consumer Staples: CENTA (28.02 -21.49%), CENT (31.25 -20.08%), SPB (46.91 -17.18%)

MacroGenics (MGNX) announced positive results from SOPHIA

MacroGenics announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients

• The SOPHIA clinical trial met the primary endpoint of prolongation of progression-free survival (PFS) in patients treated with the combination of margetuximab plus chemotherapy compared to trastuzumab plus chemotherapy. Patients in the margetuximab arm experienced a 24% risk reduction in PFS compared to patients in the trastuzumab arm (HR=0.76, p=0.033). Notably, approximately 85% of patients in the study were carriers of the CD16A (Fc?RIIIa) 158F allele, which has been previously associated with diminished clinical response to HERCEPTIN and other antibodies.
• MacroGenics anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration in the second half of 2019.

A gene mutation that makes an excess of the HER-2 protein is present in about 15% of primary invasive breast cancers, according to UpToDate, an evidence-based medical resource used by clinicians. This particular trial showed longer progression-free survival in patients treated with a combination of margetuximab and chemotherapy compared to those on trastuzumab (brand name Herceptin) and chemotherapy, a standard-of-care treatment. The company also said approximately 85% of patients in the study were carriers of the CD16A 158F allele, a gene variation has been associated with a reduced clinical response to Herceptin and other antibodies. MacroGenics said it plans to submit a biologics license application to the U.S. Food and Drug Administration in the second half of 2019.

** charts before announcement ** 

 

This week's biggest % winners & losers : Feb 26 - March 2, 18 (wk 9)

The following are this week's top 20 percentage gainers and top 20 percentage losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top 20 % gainers

• Healthcare: MGNX (28.94 +23.36%), VEEV (73.77 +19.85%), ONCE (65.67 +19.36%), ACHN (3.51 +18.78%), NKTR (102.87 +14.81%), SGYP (2.17 +14.21%)
• Materials: TAHO (4.91 +23.06%)
• Industrials: STB (7.5 +19.43%)
• Consumer Discretionary: DDS (87.97 +23.33%), ETSY (25.71 +22.02%)
• Information Technology: UBNT (67.4 +18.25%), HLIT (3.45 +16.95%)
• Financials: PHH (10.62 +22.35%), NGHC (23.55 +16.87%)
• Energy: SWN (4.47 +19.52%), TUSK (28.42 +16.48%)
• Telecommunication Services: NIHD (1.28 +24.27%), I (4.76 +20.51%)

This week's top 20 % losers

• Healthcare: AKRX (18.97 -37.02%), PTLA (34.25 -25.25%), ACAD (23.68 -24.87%), PDCO (25.01 -22.47%), VRX (14.88 -20.34%), EGRX (53.63 -19.79%), EXEL (24.08 -18.4%), RDUS (32.92 -18.02%)
• Materials: ALB (95.02 -19.98%), SQM (47.85 -18.05%)
• Industrials: BW (5.53 -20.09%)
• Consumer Discretionary: NTRI (31.45 -24.31%), ODP (2.51 -18.77%)
• Information Technology: BOX (18.82 -19.3%)
• Energy: CRC (14.98 -25.95%), HK (5.35 -23.46%), CRZO (14.9 -19.2%)
• Consumer Staples: MNST (54.16 -17.79%)
• Telecommunication Services: FTR (7.00 -23.08%)

MacroGenics (MGNX) reported earnings on Tue 27 Feb 2018 (a/h)

Biotechnology company
Headquarters: Rockville, MD
Founded: 2000
macrogenics.com

** charts 3rd day after earnings **

   

• MacroGenics tops 4Q profit forecasts

ROCKVILLE, Md. (AP) _ MacroGenics Inc. (MGNX) on Tuesday reported fourth-quarter net income of $105.7 million, after reporting a loss in the same period a year earlier.

The Rockville, Maryland-based company said it had profit of $2.80 per share.

The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $2.58 per share.

The biopharmaceutical company posted revenue of $152.4 million in the period, missing Street forecasts. Five analysts surveyed by Zacks expected $152.6 million.

For the year, the company reported that its loss narrowed to $19.6 million, or 54 cents per share. Revenue was reported as $157.7 million.

MacroGenics shares have risen 26 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $23.95, an increase of 14 percent in the last 12 months.